Wellington Management

AssetWatch specializes in proactive predictive maintenance solutions. It offers a rapidly deployable remote condition monitoring service featuring wireless sensors, communication hubs, advanced software, and expert analysis. The company combines predictive analytics with expert insights to provide actionable recommendations, helping global manufacturers minimize unplanned downtime and transition from reactive to proactive maintenance.

Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

Lumafield provides industrial computed tomography solutions for non-destructive testing and inspection in engineering environments. Its Neptune X-ray CT scanner enables detailed imaging to analyze internal structures and detect defects across materials. The Voyager software platform delivers cloud-based AI-powered analysis, automated inspections, and collaboration tools to support product development from design through manufacturing. Triton is a high-speed CT system designed for rapid scanning in high-volume manufacturing settings. The company serves industries including aerospace, automotive, electronics, and medical devices, helping to improve product quality and reliability through advanced imaging and analysis capabilities.

SiteOne Therapeutics is a San Francisco-based company developing innovative therapeutics and diagnostics for acute and chronic pain. Their lead candidates are selective inhibitors of the Naᵥ1.7 ion channel, aiming to treat pain safely and effectively without relying on NSAIDs or opioids.

MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Bluejay Therapeutics is a private biopharmaceutical company focused on developing curative treatments for infectious and liver diseases. Its initial program targets chronic hepatitis B, a widespread infection with unmet medical need, using two approaches: fully human IgG1 monoclonal antibodies against hepatitis B surface antigen and oral small-molecule inhibitors of HBsAg. The aim is to reduce viral surface antigen and restore adaptive immunity, potentially achieving a functional cure for HBV and enabling patients to regain immune control of infection. The company’s work also contemplates extending its approach to other viral liver diseases, including chronic hepatitis D.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.

Quince, LLC, established in 2016 and headquartered in San Francisco, California, is a retailer specializing in affordable luxury apparel, accessories, and home goods. The company offers a wide range of products for men and women, including jewelry, clothing, and home textiles, all sourced directly from manufacturers using a just-in-time production model. This approach enables Quince to provide high-quality items at competitive prices while minimizing waste.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Skims is a brand specializing in underwear, loungewear, and shapewear designed to enhance and complement various body shapes. They offer a wide range of products including bodysuits, shapewear, and underwear in diverse styles and colors to provide women with optimal support and coverage.

Musinsa Co., Ltd. is a fashion-focused company based in Seoul, South Korea, established in 2012. It operates both online and offline, offering a diverse range of products that include apparel, footwear, accessories, cosmetics, and more. Musinsa serves as a platform for various brands, including subculture, national, and global sports brands, providing customers with curated content, styling pictorials, and information on fashion trends. The company emphasizes customer engagement by allowing users to interact with brands and access personalized curation and storytelling. Additionally, Musinsa publishes an online fashion web magazine that showcases product information and brand highlights, further enriching the fashion culture and consumption experience in the Korean market.

Boundless Bio develops innovative cancer therapeutics focused on understanding and treating previously untreatable cancers. It specializes in targeting extrachromosomal DNA (ecDNA) biology, a key driver of aggressive cancers.

AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.

AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.

Meati Foods produces and sells fungi-based meat alternatives. Founded in 2016, the company uses proprietary clean technologies to create nutrient-dense, plant-based products that are free from common allergens.

Juspay Technologies Pvt Ltd. is a Bengaluru-based company, founded in 2012, that specializes in mobile payment solutions. It offers a suite of products, including JUSPAY SAFE, a mobile payments browser, and EXPRESS CHECKOUT, which enhances payment gateway performance. The company's online platform serves as a software-as-a-service layer over existing payment gateways, streamlining integration and improving the management of various payment options. This enables users to conduct electronic transactions securely and efficiently, catering to the evolving needs of mobile-based payments.

Course Hero operates as an online learning platform dedicated to providing study resources for students and educators. Founded in 2006 and based in Redwood City, California, the company offers a range of materials including lecture notes, study guides, textbook help, practice problems, exams, and video lectures from universities across the United States and internationally. Course Hero's platform is subscription-based and includes an educator platform for distributing materials and publishing content. Additionally, it features a flashcards application and access to expert tutors who assist students with their queries. The company was previously known as TheCollegeFreeway.

Teya is a comprehensive platform serving over 300,000 business owners worldwide. It offers payment processing, loyalty programs, cash advances, and business management tools, empowering small and growing businesses to thrive.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Sundae is a residential real estate marketplace designed to assist homeowners in selling their properties off-market. The company's platform caters specifically to individuals looking to sell dated or damaged homes without the hassle of traditional real estate processes, which often involve repairs, cleaning, and showings. Sundae allows sellers to list their homes as-is and on their own timeline, streamlining the selling experience. By connecting homeowners with a broad network of local investors, Sundae ensures that sellers receive competitive off-market prices for their properties, thus providing a fair alternative to conventional home sales.

Lendbuzz, Inc. is a Boston-based company that operates an innovative car financing platform aimed at individuals with limited or no credit history, such as international students, foreign professionals, and expatriates. Founded in 2015, Lendbuzz uses machine learning algorithms and proprietary technology to assess the creditworthiness of consumers who are typically underserved by traditional financial institutions. By evaluating background information, including employment and educational history, the platform provides tailored car loans and financing solutions with favorable terms and low-interest rates. Lendbuzz partners with auto dealerships to enhance their offerings, allowing them to serve a more diverse clientele and close additional business opportunities. The company emphasizes a streamlined documentation process, making it easier for clients to access and manage their loans.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

Cityblock Health, Inc., established in 2017 and headquartered in Brooklyn, New York, operates a personalized health system tailored to meet the unmet health and social needs of Medicaid and Medicare populations. The company's online platform offers integrated primary care, behavioral health, and virtual care services, along with a tool called Commons for communication, information sharing, and task management. Cityblock's model focuses on upstream investment in highly personalized, prevention-oriented care, aiming to improve outcomes and reduce costs. It partners with community-based organizations to deliver care, enabling clinicians to provide personalized care for each member. During the COVID-19 pandemic, Cityblock developed a model to help identify high-risk members within organizations.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Cityblock Health, Inc., established in 2017 and headquartered in Brooklyn, New York, operates a personalized health system tailored to meet the unmet health and social needs of Medicaid and Medicare populations. The company's online platform offers integrated primary care, behavioral health, and virtual care services, along with a tool called Commons for communication, information sharing, and task management. Cityblock's model focuses on upstream investment in highly personalized, prevention-oriented care, aiming to improve outcomes and reduce costs. It partners with community-based organizations to deliver care, enabling clinicians to provide personalized care for each member. During the COVID-19 pandemic, Cityblock developed a model to help identify high-risk members within organizations.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

Current is a consumer fintech banking platform dedicated to enhancing financial access for everyday Americans. The company focuses on developing integrated solutions that address the barriers preventing individuals from achieving their financial goals. By simplifying banking processes and providing user-friendly tools, Current aims to empower users to build a secure financial future. With backing from prominent investors, Current continues to innovate in the financial technology space, striving to meet the diverse needs of its customer base through modern banking solutions.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer treatment. Based in Shanghai, China, Gracell's lead product candidates include GC012F, a dual-targeting autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia. Both candidates are currently undergoing Phase I clinical trials. Additionally, the company is advancing GC007F for B cell non-Hodgkin's lymphoma and GC027 for adult T cell acute lymphoblastic leukemia, among others. Gracell also has a range of earlier-stage product candidates addressing various cancer types, such as ovarian cancer and breast cancer. Founded in 2017, the company aims to provide effective cellular therapeutics to improve outcomes for patients with hematological malignancies and solid tumors.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.

Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.

Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

Black Diamond Therapeutics discovers and develops small molecule therapies for precision oncology. It focuses on allosteric mutations in kinases related to cancer, with a lead product candidate targeting non-canonical ErbB kinase mutations.

Atreca is a biopharmaceutical company that discovers and develops antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from its proprietary discovery platform.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Nightstar Therapeutics is a clinical-stage gene therapy company based in London, United Kingdom, specializing in the development of innovative one-time treatments for rare inherited retinal diseases. The company is advancing several product candidates, including its lead candidate NSR-REP1, which is in phase 3 clinical development for choroideremia. Additionally, Nightstar is working on NSR-RPGR, currently in phase 2/3 trials for X-linked retinitis pigmentosa, as well as NSR-BEST1. The company is also developing NSR-ABCA4, which is in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address significant unmet medical needs in the field of retinal disorders.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

The Trade Desk is a technology company that provides a self-service, cloud-based platform for managing digital advertising campaigns. The platform enables advertisers and agencies to buy and optimize data-driven media across display, video, audio, native, and social formats on computers, mobile devices, and connected TV. It uses data and iterative optimization to improve the performance of ad impressions and supports campaign management with additional features. The company serves advertisers and advertising agencies worldwide and derives revenue from fees based on a percentage of client spend through its demand-side platform.

Magic Leap is an American startup specializing in Augmented Reality (AR) technology. The company develops proprietary wearable hardware that merges digital imagery with the real world, creating immersive AR experiences indistinguishable from reality. Their innovative Dynamic Digitized Lightfield Signal generates computer-generated 3D images that harmonize with human senses, enabling users to interact with digital devices in a visually cinematic manner. Magic Leap aims to redefine how users access screens and visualize data by combining inherent visual ability with mobile computing technology.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.

Rubicon is a software platform offering full-service waste management, recycling, and smart city solutions through a digital marketplace for waste and recycling services. It focuses on transparency and data-driven decision making to improve operational efficiency and sustainability for businesses and governments. The company provides software products that connect customers with waste service providers and support efficient, transparent, and environmentally responsible waste management.

TabbedOut puts you in control of your tab at bars and restaurants. Say goodbye to end-of-night bar lines, and flagging down your server when you’re ready to settle the bill. Never leave your card at the bar again! TabbedOut is easier and more secure than handing over your credit card to a stranger. Open a tab, view the running total, and pay for it instantly (and securely) all from your phone. You can even split your tab among friends, post to Facebook or Twitter to let your friends know where you’re dining, send a positive or negative review of your experience, and get offers sent from your favorite venue straight to your phone. TabbedOut takes the hassle out of dining out for good. We are adding new locations every day, so check in often on the locations screen. Don’t see your favorite bar or restaurant on the list? Let us know! Tweet at or Facebook us at @tabbedout. For merchants: TabbedOut is the premier marketing and analytics platform built exclusively for the hospitality industry and powered by mobile payments. We allow our merchants real time insight into their customers through our proprietary software system that tracks spending habits, product preferences, customer feedback and loyalty rewards. Best of all, TabbedOut allows you, the merchant, to accept mobile payments integrated into your POS system. Finally, POS systems and mobile payments meet customer marketing and rewards in real time. That’s the power of TabbedOut! Free to download and no hidden fees.

Founded in 2012, Harry's is a New York-based company that manufactures and sells high-quality shaving products. Its product range includes razors, shaving creams, grooming kits, and face care products, available both individually and through a subscription service.

Oscar Health is a health insurance company based in New York, founded in 2012 by Joshua Kushner, Kevin Nazemi, and Mario Schlosser. It specializes in offering individual and family health insurance plans, Medicare Advantage programs for seniors, and small group products. Oscar Health aims to enhance the healthcare experience by leveraging technology, design, and data to make services more accessible and user-friendly. The company primarily serves individuals, couples, and families who do not receive employer-sponsored health insurance in select states, including New York, New Jersey, California, and Texas. In addition to traditional insurance offerings, Oscar provides virtual care, doctor support, and appointment scheduling, emphasizing a comprehensive approach to healthcare management.

Blueprint Medicines is a Cambridge, Massachusetts-based biopharmaceutical company that develops targeted, small-molecule therapies to treat genomically defined cancers, rare diseases, and related conditions. The company focuses on precision medicines that address molecular drivers and resistance mechanisms, advancing a pipeline that includes avapritinib for systemic mastocytosis and certain gastrointestinal stromal tumors, BLU-263, a KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders, fisogatinib for advanced hepatocellular carcinoma, and pralsetinib, a RET inhibitor for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. It is also pursuing BLU-782, an ALK2 inhibitor in early clinical trials for fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with partner companies such as Clementia Pharmaceuticals, CStone Pharmaceuticals, Genentech, and Hoffmann-La Roche. Founded in 2008, the company operates in the United States and Europe and combines its Insights-to-Validation platform with a proprietary chemical library to discover and develop new therapeutic compounds and combination therapies in oncology, hematology, and related areas.

Powa Technologies is an international commerce specialist based in London, United Kingdom, that focuses on integrating physical and digital retail experiences. The company offers a suite of technologies designed to enhance e-commerce, including PowaTag, a mobile application that facilitates payments through codes that can be applied to various marketing media such as billboards and advertisements. In addition to PowaTag, Powa Technologies provides several other products, including PowaWeb, powaPos, and PowaPIN, which collectively support the development of scalable online shops and enable an agile e-commerce environment. Established in 2007, Powa Technologies operates as a subsidiary of SuperCom Ltd.

The Honest Company, Inc. is a consumer products firm based in Santa Monica, California, established in 2011. It specializes in designing and manufacturing a diverse range of eco-friendly and affordable products aimed at families and homes. The company's offerings include bundles for babies, bath and body care, cleaning supplies, and health and wellness products. Prominent items in their portfolio consist of eco-friendly diapers and wipes, skincare products, household cleaners, and organic nutritional supplements. The Honest Company operates through both retail and digital channels, ensuring broad accessibility for consumers. Its revenue is primarily driven by the sale of diapers and wipes, emphasizing the brand's commitment to convenience and sustainability.

Civitas Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative pulmonary delivery therapies aimed at treating central nervous system and respiratory disorders. Utilizing its proprietary ARCUS technology, Civitas aims to transform the therapeutic landscape for patients across the United States. The company's focus is on creating effective treatments that enhance patient outcomes and address unmet medical needs in these critical areas.

Datalogix is a prominent company specializing in connecting digital media with offline purchasing data, enabling marketers to enhance the effectiveness and measurability of their advertising efforts. The company serves more than half of the top 100 consumer marketers and manages the DLX Platform, which encompasses over $1 trillion in consumer spending and supports campaigns for a significant majority of online media companies. Datalogix's DLX ROI is becoming a standard for measuring the impact of digital media on offline sales. Additionally, the company provides predictive analytics for direct mail and integrated media solutions through the DLX Net. Its expertise covers various consumer sectors, including retail, consumer packaged goods, automotive, telecommunications, travel, and financial services. Headquartered in Colorado, Datalogix has established offices in key cities such as New York City, San Francisco, Boston, Chicago, Detroit, and London.

Malauzai Software, Inc., established in 2009 and headquartered in Austin, Texas, specializes in developing mobile and internet banking solutions tailored for community financial institutions. The company offers a suite of SmartApps, SmartwebApps, and SmartwearApps, catering to consumers, small businesses, and employees, enabling them to manage their financial transactions across various devices. Malauzai's flagship product, the MOX enterprise platform, streamlines management of these solutions on a single platform. The company's products aim to enhance the customer experience and increase value for financial institutions, focusing primarily on community banks and credit unions. Since 2018, Malauzai has operated as a subsidiary of Finastra Group Holdings Limited.

SensAble Technologies, Inc. specializes in the development of force-feedback haptic devices and touch-enabled 3D modeling software solutions. The company offers a range of products, including FreeForm Modeling Systems for medical and dental applications, product design, and digital content creation, as well as The SensAble Dental Lab System for scanning and 3D fabrication. Its PHANTOM Haptic Devices provide force feedback and 3D navigation, while the OpenHaptics software toolkit enables the development of haptic applications. SensAble serves diverse industries such as automotive, dental, fine arts, gaming, and medical, with applications in product design, surgical simulation, and robotic research. Founded in 1993 and based in Woburn, Massachusetts, the company also maintains a sales office in Tokyo, Japan.